Atai stocks.

35,390.15 +117.12(+0.33%) Nasdaq -15.00(-0.11%) Russell 2000 1,807.50 +11.96(+0.67%) Crude Oil 75.54 -1.56(-2.02%) Gold 2,003.00 +10.20(+0.51%) Atai Life Sciences N.V. (ATAI) NasdaqGM -...As per our price and time readings, we forecast that November of 2023 will be a bullish month. This could set the stage for a test of ATH early 2024. While price analysis is very important, often leading for decisions, our thesis is that time analysis is even more important to understand periods in which ‘good things tend to happen’ vs ...WebLooking for the best stocks under $2 to buy in 2023? MarketBeat has identified 25 low-priced stocks that you should consider for your portfolio. Skip to main content. S&P 500 4,594.63. DOW 36,245.50. ... #12 - Atai Life Sciences NASDAQ:ATAI Stock Price: $1.12 (+$0.08) PE Ratio: ...WebNov 29, 2023 · According to 4 analysts, the average rating for ATAI stock is "Strong Buy." The 12-month stock price forecast is $13.5, which is an increase of 1,110.76% from the latest price.

The stock has given up three-quarters of its market value year to date. Ark Genomic bought 67,384 shares of Atai Life Sciences - Get Free Report, valued at $284,360. Atai is a Berlin ...Pros and cons to owning his top 5 stocks. ... Atai, I find to be very interesting and I could see them being the blueprint for almost like a VC model of how to do psychedelic drug development ...How many ATAI shares are owned by institutional investors? 24.8M ATAI shares ... Trading stocks, options and other securities involves risk. The risk of loss ...

According to 4 analysts, the average rating for ATAI stock is "Strong Buy." The 12-month stock price forecast is $13.5, which is an increase of 1,105.36% from the …ATAI Life Sciences NV’s trailing 12-month revenue is $0.3 million with a % profit margin. Year-over-year quarterly sales growth most recently was %. Analysts expect adjusted earnings to reach $-0.317 per share for the current fiscal year. ATAI Life Sciences NV does not currently pay a dividend.

ATAI Life Sciences is a biopharmaceutical company focused on developing psychedelic-based treatments for mental health conditions. The company has a diverse portfolio of drug candidates in various ...Jun 18, 2021 · Shares of the Peter Thiel -backed psychedelic start-up Atai Life Sciences jumped Friday on their first day of trading on Wall Street. The newly listed Nasdaq stock opened up 40% before pulling ... Shares of mental health biopharma Atai Life Sciences N.V. have fallen some two-thirds from their June 2021 IPO pricing as the biotech market continues to crater. See why ATAI stock is a buy.Nov 29, 2023 · 4 brokers have issued 1-year price targets for Atai Life Sciences' stock. Their ATAI share price targets range from $9.00 to $20.00. On average, they expect the company's stock price to reach $12.80 in the next twelve months. This suggests a possible upside of 1,063.6% from the stock's current price. A community of stock market investors in the legal psychedelics sector. Global drug policy is changing, and psychedelic therapies are next in line for decriminalization, research, and sale. ... Florian Brand and Srinivas Rao from ATAI Life Sciences-- 03/24/2023. Ronan Levy from Field Trip Health-- 11/22/2022.

In 2019 ATAI had a net loss of $24,384,000. They had basically no income (as would be expected from any nascent company developing new drugs). Roughly $3 million was spent on R&D, almost $10 million on acquiring programs, and $5 million on general/administrative expenses. In 2020 ATAI has a net loss of $178,000,000.

Atai stock closed up 30% at 19.45 on the stock market today, paring gains after surging more than 50% earlier. Credit Suisse, Citigroup, Cowen, and Berenberg were book-running managers for the ...

According to Accountingbase.com, common stock is neither an asset nor a liability; it is considered equity. Equity is basically considered to mathematically be the difference between the total assets and total liabilities of a company.ATAI Stock Price Today by TradingView. Atai Life Sciences (NASDAQ: ATAI) is “a biopharmaceutical company that leverages a decentralized platform approach to incubate and accelerate the development of highly effective mental health treatments.” Like many companies on this list, they are working on treatments for mental health issues like ...Mar 24, 2023 · atai’s development candidates, such as RL-007 and GRX-917, all represent significant opportunities to address unmet medical needs of patients living with mental health conditionsContinued ... Stock Data; Quote. Stock Data. Quote · Charts · Historical Data. ATA Creativity ... ® Copyright 2023 atai.net.cn ATA Group All rights reserved 沪ICP备14030601号- ...3:24 pm. Articles. atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine) August 10, 2023 Advanced multiple clinical stage assets in development, including the on-going Phase 2b study of RL-007 in patients…. August 10, 2023.At Compass’ current market cap of ~$1.1 billion, ATAI has a $200 – 300 million stake in the company. This gives ATAI’s valuation a sort of floor dependent on Compass’ ultimate market cap. It will be just as important for Compass to succeed over the coming months as it will for ATAI’s portfolio companies to perform.Web

Atai stock closed at $17.38 in Friday's trading session. Other coverage included an Outperform from Credit Suisse with a price target of $25; Buy ratings from Citigroup. HOME. MAIL.WebFind the latest Earnings Report Date for ATAI Life Sciences N.V. Common Shares (ATAI) at Nasdaq.com.ATAI Nasdaq Stock Market • delayed by 15 minutes • CURRENCY IN USD • Biotechnology & Medical Research. ATAI Life Sciences NV (ATAI) Compare.WebAtai already has an MDMA-derived drug in its pipeline, EMP-01, in collaboration with Empath Bio. If the FDA approves MDMA, it will help Atai as it will further interest and investments into the ...ATAI stock, a health technology company in the pharmaceutical industry, had a mixed performance on November 21, 2023, according to data from CNN Money. The stock opened at $1.10 and traded within a narrow range of $1.09 to $1.11. The trading volume was relatively low at 18,798 shares. ATAI has a market capitalization of $182.6 million.Key Stock Data · P/E Ratio (TTM). N/A · EPS (TTM). $-0.42 · Market Cap. $185.93 M · Shares Outstanding. 166.01 M · Public Float. 114.08 M · Yield. ATAI is not ...

Stock Data; Quote. Stock Data. Quote · Charts · Historical Data. ATA Creativity ... ® Copyright 2023 atai.net.cn ATA Group All rights reserved 沪ICP备14030601号- ...Atai Life Sciences N.V. (ATAI.NASDAQ) : Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Atai Life Sciences N.V. | Nasdaq: ...

ATAI stock closed at $1.76 and is up $0.10 during pre-market trading. Pre-market tends to be more volatile due to significantly lower volume as most investors only trade between standard trading hours. ATAI has a strong overall score of 70 meaning the stock holds a better value than 70% of stocks at its current price.TipRanks | Stock Market Research, News and Analyst Forecasts - TipRanks.comWebATAI Life Sciences Stock (NASDAQ:ATAI), Guidance and Forecast benzinga.com - August 13 at 4:19 AM: ATAI Life Sciences Stock (NASDAQ:ATAI), Short Interest Report benzinga.com - August 12 at 11:19 PM: ATAI Life Sciences (ATAI) Receives a Buy from Berenberg Bank markets.businessinsider.com - August 11 at 5:09 PM:Nov 18, 2022 · (See ATAI stock forecast on TipRanks) SomaLogic . The next Wood pick we’ll look at is a protein biomarker discovery and clinical diagnostics company. SomaLogic operates in what is known as the ... Data sources: Yahoo! Finance and company websites. Market caps as of Oct. 23, 2023. Company Market Cap Description Atai Life Sciences (NASDAQ:ATAI) $215.8 millionAccording to the issued ratings of 4 analysts in the last year, the consensus rating for Atai Life Sciences stock is Buy based on the current 4 buy ratings for ATAI. The average twelve-month price prediction for Atai Life Sciences is $12.80 with a high price target of $20.00 and a low price target of $9.00. Learn more on ATAI's analyst rating ... Mar 27, 2023 · 0. These 7 analysts have an average price target of $13.29 versus the current price of ATAI Life Sciences at $1.3447, implying upside. Below is a summary of how these 7 analysts rated ATAI Life ... Find the latest Atari SA (ALATA.PA) stock quote, history, news and other vital information to help you with your stock trading and investing.

PONGF | Complete Atari S.A.S. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

Atai Life Sciences (NASDAQ: ATAI) is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. In the first week of the new year, the stock plummeted when the failed results of ATAI's NYC-based subsidiary, Perception Neuroscience's Phase 2a study of proprietary R-ketamine PCN-101 on patients with ...

Florian Brand's Atai Life Sciences went public three years after launching, fueled by Silicon Valley interest and promising science, but it's still waiting for its first big breakthrough.Atai Life Sciences has a strong pipeline of drugs for the next 18 months, and will pursue aggressive growth. The company had $335 million in cash as of May 2022, which is roughly 50% of its ...Atai Life Sciences (NASDAQ: ATAI) Psychedelic stocks have performed about as well as marijuana stocks over the last few months. Given the general uncertainties surrounding the future of recreational legislation, mass adoption from investors hasn’t necessarily been a trend. Nevertheless, that hasn’t stopped some from staking a claim in …Dec 4, 2023 · ATAI stock closed at $1.12 and is down -$0.08 during pre-market trading. Pre-market tends to be more volatile due to significantly lower volume as most investors only trade between standard trading hours. ATAI has a poor overall score of 33 meaning the stock holds a better value than just 33% of stocks at its current price. Oct 2, 2023 · atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders and was founded as a response to the significant unmet need and lack of innovation ... May 25, 2023 · This influential firm issued a $20 share price target for ATAI, propelling its stock value to surge. As of May 24, 2023, ATAI Life Sciences boasts an average one-year price target of $13.75, as ... Find the latest Earnings Report Date for ATAI Life Sciences N.V. Common Shares (ATAI) at Nasdaq.com.who we are: atai is a global biotech company builder that leverages a decentralized, technology- and data-driven platform model to serve millions of people ...From July 5 to July 7, the ARK Genomic Revolution ETF purchased 268,974 shares of ATAI Life Sciences (NASDAQ: ATAI). This was the ETF and Ark Invest’s first purchase of ATAI stock since March 14.Atai Life Sciences Announces Results from the Phase 1 Iv-To-Subcutaneous Bridging Study of Pcn-101 (R-Ketamine) Aug. 08: CI Atai Life Sciences N.V., Atai Life Sciences AG Enters into the Second Amendment to Loan and Security Agreement with the Several Banks May. 31: CIPONGF | Complete Atari S.A.S. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

ATAI Life Sciences. ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01 ...Mar 24, 2023 · atai’s development candidates, such as RL-007 and GRX-917, all represent significant opportunities to address unmet medical needs of patients living with mental health conditionsContinued ... The upgrade of atai Life Sciences N.V. to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the ...Find the latest Earnings Report Date for ATAI Life Sciences N.V. Common Shares (ATAI) at Nasdaq.com.Instagram:https://instagram. t rowe price global stock fundfx vpsbarron's stock pickstruck stocks From July 5 to July 7, the ARK Genomic Revolution ETF purchased 268,974 shares of ATAI Life Sciences (NASDAQ: ATAI). This was the ETF and Ark Invest’s first purchase of ATAI stock since March 14. hubspot stocksfscfx Atai Life Sciences ( ATAI 2.80%), a small-cap drugmaker developing psychedelic-based treatments for drug dependency and mental health disorders, posted strong gains during the first four days of ... nintendp stock Complete ATAI Life Sciences N.V. stock information by Barron's. View real-time ATAI stock price and news, along with industry-best analysis.With its shares down by 60% in the last 12 months and a recent layoff affecting 30% of its workforce, it's fair to say that Atai Life Sciences ( ATAI 1.87%) is having a rough go of things lately ...NEW YORK and BERLIN, Jan. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “the Company”), a clinical-stage biopharmaceutical company focused on mental health ...